ADMA Biologics appoints Alison C. Finger to board as Class I director

ADMA BIOLOGICS, INC.

Alison C. Finger appointed to board effective Sept 28, 2023; term expires at 2026 annual meeting.
Ms. Finger was Chief Commercial Officer at bluebird bio (Aug 2015-Jan 2021) and held VP roles at BMS.
Initial grant of options to purchase 98,870 shares of common stock upon joining the board.
No arrangements or transactions requiring disclosure under Item 404(a) exist.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Alison C. Finger

Class I director

ADMA · ADMA BIOLOGICS, INC.

Effective: 2023-09-28
Filed: October 2, 2023, 7:59 PM ET

On September 28, 2023, the Board of Directors (the “Board”) of ADMA Biologics, Inc. (the “Company”) appointed Alison C. Finger to serve on the Board as a Class I director with a term expiring at the Company’s 2026 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Alison C. Finger was appointed as Class I director at ADMA BIOLOGICS, INC..

Action: appointed
Role: Class I director

Exact text from the filing

On September 28, 2023, the Board of Directors (the “Board”) of ADMA Biologics, Inc. (the “Company”) appointed Alison C. Finger to serve on the Board as a Class I director with a term expiring at the Company’s 2026 annual meeting of stockholders.

View on SEC.gov

ADMA BIOLOGICS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-23-046335

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.